Insmed (INSM) vs Zoetis (ZTS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Insmed (INSM) has outperformed Zoetis (ZTS) over the past year, losing 37.9% versus a loss of 49.1%. Over five years, INSM leads with a +279.3% price change compared with -63.9% for ZTS. Zoetis is the larger company by market cap ($30.76 billion vs $21.90 billion), about 1.4 times the size, while Insmed is growing revenue faster (+66.7% vs +2.3%).
On valuation, Zoetis trades at a lower forward P/E (11.4x vs 127.4x for Insmed). Zoetis pays a dividend yielding 2.77%, while Insmed does not currently pay one. Zoetis converts more of its revenue into profit, with a net margin of 28.2% versus -210.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INSM | ZTS |
|---|---|---|
| Share price | $100.30 | $74.44 |
| Market cap | $21.90B | $30.76B |
| 1-day change | -0.18% | +1.86% |
| YTD return | -42.27% | -41.92% |
| 1-year return | -37.90% | -49.07% |
| 5-year return | +279.31% | -63.86% |
| P/E ratio (TTM) | — | 12.24 |
| Forward P/E | 127.38 | 11.37 |
| EPS (TTM) | $-4.10 | $6.08 |
| Dividend yield | 0.00% | 2.77% |
| Annual dividend | $0.00 | $2.06 |
| Revenue (latest FY) | $606.42M | $9.47B |
| Revenue growth (YoY) | +66.73% | +2.28% |
| Net income (latest FY) | $-1.28B | $2.67B |
| Gross margin | 79.73% | 71.84% |
| Operating margin | -205.59% | — |
| Net margin | -210.54% | 28.23% |
| 52-week high | $212.75 | $148.30 |
| 52-week low | $90.39 | $68.77 |
| Distance from 52-week high | -52.86% | -49.80% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +97.15% | +28.96% |
| Average volume | 2.60M | 5.46M |
| Shares outstanding | 218.38M | 413.22M |
| Employees | 1,664 | 14,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INSM has outperformed ZTS by 11.2 percentage points over the past year.
- Zoetis offers a meaningfully higher dividend yield (2.77% vs 0.00%).
- Zoetis is more profitable, keeping 28.2 cents of every revenue dollar as net income versus -210.5 cents for Insmed.
- Insmed grew revenue faster in its latest fiscal year (+66.73% vs +2.28%).
About Insmed
INSM stock →Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,664 employees
About Zoetis
ZTS stock →Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 14,500 employees
INSM vs ZTS FAQ
Which is bigger, Insmed or Zoetis?
Zoetis (ZTS) is larger, with a market capitalization of $30.76B compared with $21.90B for Insmed (INSM).
Which stock has performed better over the past year, INSM or ZTS?
INSM returned -37.90% over the past 12 months, compared with -49.07% for ZTS (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Insmed or Zoetis?
Zoetis pays a dividend yielding 2.77%, while Insmed does not currently pay a regular dividend.
Are Insmed and Zoetis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.